Is there a point at which further reduction in amyloid burden is no longer clinically meaningful or should the goal always be as much reduction as possible?
I suspect the treatment effect is seen primarily in patients who achieve substantial reduction in amyloid, but I have not seen adequate data showing definitive correlations. How long to treat and how to monitor treatment response are open questions in the field. Amyloid burden was measured in the tr...
I do not think we know the answer for this question yet. The TRAILBLAZER-ALZ 2 study, however, seems to suggest that below a certain threshold further reduction in amyloid burden might not be necessary.
Currently, there are no published stopping criteria for aducanumab or lecanemab. The donanemab study did include prespecified stopping critiera based on amyloid plaque clearance, so if it gets FDA approved, this criteria will likely be incorporated into clinical practice. In the future, there may be...